资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney Function.

J. Am. Soc. Nephrol.. 2019;

ThomasLinto，XueJianxiang，MuraliSathish Kumar，FentonRobert A，Dominguez RiegJessica A，Rieg

Products/Services Used	Details	Operation
Biochemicals	22,23,25 PTH Administration Mice were randomized to either acute application of PTH vehicle (sterile water, 2 ml/g body wt, intraperitoneally) with Npt2a-I vehicle (see above, oral gavage), PTH (200 mg/kg body wt, intraperitoneally ; GenScript, Piscataway, NJ)23,26,27 with Npt2a-I vehicle, PTH vehicle with Npt2a-I, or PTH with Npt2a-I.	Get A Quote

摘要

The kidneys play an important role in phosphate homeostasis. Patients with CKD develop hyperphosphatemia in the later stages of the disease. Currently， treatment options are limited to dietary phosphate restriction and oral phosphate binders. The sodium-phosphate cotransporter Npt2a， which mediates a large proportion of phosphate reabsorption in the kidney， might be a good therapeutic target for new medications for hyperphosphatemia.